Protocol · Neurological Health
Chronic Progressive External Ophthalmoplegia (CPEO) Supportive Care Protocol
Coenzyme Q10 and L-Carnitine are the core of this stack, with 7 supporting supplements. Each row gives the amount the protocol lists and the grade our evidence database holds for that supplement in Chronic Progressive External Ophthalmoplegia (CPEO) Supportive Care.
We are re-verifying the studies cited on protocol pages; only confirmed citations are shown.
The stack
9 supplements · none graded yet
| Grade | Supplement | Amount listed | Why it’s in the stack | Evidence on file |
|---|---|---|---|---|
| Primary stackThe core of this protocol | ||||
| Coenzyme Q10 | Amount listed: 300–600 mg daily (ubiquinol form preferred for absorption) | Essential for mitochondrial function; CPEO is a mitochondrial disorder; may support cellular energy production | Not graded yet | |
| L-Carnitine | Amount listed: 2–3 g daily in divided doses | Supports fatty acid transport into mitochondria for energy production; often deficient in mitochondrial disorders | Not graded yet | |
| Supporting stackListed as additions to the core | ||||
| Riboflavin (Vitamin B2) | Amount listed: 100–400 mg daily | Cofactor for mitochondrial electron transport; may support residual complex I and II function | Not graded yet | |
| Alpha-Lipoic Acid | Amount listed: 300–600 mg daily | Antioxidant and mitochondrial cofactor; may reduce oxidative stress in mitochondrial disease | Not graded yet | |
| Creatine | Amount listed: 5–10 g daily | Provides alternative energy source for muscle; may help with fatigue and exercise intolerance
| Not graded yet | |
| Vitamin E | Amount listed: 400–800 IU daily (mixed tocopherols) | Antioxidant; protects mitochondrial membranes from oxidative damage | Not graded yet | |
| B-Complex Vitamins | Amount listed: High-potency B-complex daily | Multiple B vitamins are mitochondrial cofactors; thiamine, niacin, pantothenic acid especially important | Not graded yet | |
| Idebenone | Amount listed: 150–360 mg daily in divided doses | Synthetic CoQ10 analog; may cross cell membranes better; studied for mitochondrial disorders | Not graded yet | |
| Vitamin D | Amount listed: 2,000–4,000 IU daily | Supports muscle function; often low in mitochondrial myopathies | Not graded yet | |
How this protocol works
In plain language
Chronic Progressive External Ophthalmoplegia (CPEO) is a mitochondrial disease that primarily affects the muscles that control eye movement. It causes slowly progressive drooping of the eyelids (ptosis) and difficulty moving the eyes (ophthalmoplegia). Many patients also develop weakness in other muscles (limbs, swallowing, heart).
CPEO is caused by defects in mitochondrial DNA - the 'powerhouses' of cells that produce energy. When mitochondria don't work properly, muscles that need the most energy (like eye muscles and heart) are affected first.
IMPORTANT: There is currently no cure for CPEO. Treatment is supportive.
MEDICAL MANAGEMENT includes:
- Ptosis surgery: For severe eyelid drooping affecting vision
- Strabismus surgery: For eye misalignment
- Prism glasses: To help with double vision
- Cardiac monitoring: Regular ECG and echocardiograms (heart block is a concern)
- Physical therapy: To maintain strength and function
- Swallowing evaluation: If dysphagia develops
MITOCHONDRIAL COCKTAIL:
Many specialists recommend a combination of supplements to support mitochondrial function:
CoQ10* is essential for the electron transport chain. While evidence is limited, it's considered standard supportive care.
L-Carnitine* transports fatty acids into mitochondria for energy production.
Riboflavin (B2)* and other B vitamins are mitochondrial cofactors.
Alpha-Lipoic Acid* is an antioxidant that also functions as a mitochondrial cofactor.
Creatine* may provide an alternative energy source for muscles.
Expected timeline: CPEO is a slowly progressive condition. Supplements may help slow progression or improve energy levels, but cannot reverse the disease. Regular monitoring for cardiac and other complications is essential.